Ask AI
Public Law115th CongressHealth
S. 920Became Law

National Clinical Care Commission Act

This bill became law

Filed
Comm.
Floor
Both
Law

What it doesSummary public law (Nov 2, 2017)

(This measure has not been amended since it was passed by the Senate on September 6, 2017. The summary of that version is repeated here.)

National Clinical Care Commission Act

(Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, (4) methods for outreach and dissemination of education and awareness materials, and (5) opportunities for consolidation of overlapping federal programs.

The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

What just happenedNov 2, 2017

Signed by President.

Who’s behind it

Sen. Shaheen, Jeanne [D-NH](D-NH)Sponsor
2 cosponsors1 D1 R
Read on Congress.gov
2cosponsors1committees22actions1amendments8subjects
  1. Nov 2, 2017President

    Signed by President.

  2. Nov 2, 2017BecameLaw36000

    Signed by President.

  3. Oct 24, 2017Floor

    Presented to President.

  4. Oct 24, 2017President28000

    Presented to President.

  5. Oct 11, 2017FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  6. Oct 11, 2017FloorH37300

    On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H7946)

  7. Oct 11, 2017Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H7946)

  8. Oct 11, 2017FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on S. 920.

  9. Oct 11, 2017FloorH30000

    Considered under suspension of the rules. (consideration: CR H7946-7948)

  10. Oct 11, 2017FloorH30300

    Mr. Olson moved to suspend the rules and pass the bill.

  11. Sep 7, 2017FloorH15000

    Held at the desk.

  12. Sep 7, 2017FloorH14000

    Received in the House.

  13. Sep 7, 2017Floor

    Message on Senate action sent to the House.

  14. Sep 6, 2017Floor

    Passed Senate with amendments by Unanimous Consent. (text: CR S5019-5020)

  15. Sep 6, 2017Floor17000

    Passed/agreed to in Senate: Passed Senate with amendments by Unanimous Consent.(text: CR S5019-5020)

  16. Sep 6, 2017Floor

    Measure laid before Senate by unanimous consent. (consideration: CR S5019-5020)

  17. May 1, 2017Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 47.

  18. May 1, 2017Committee

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander without amendment. Without written report.

    Health, Education, Labor, and Pensions Committee
  19. May 1, 2017Committee14000

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander without amendment. Without written report.

    Health, Education, Labor, and Pensions Committee
  20. Apr 26, 2017Committee

    Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.

    Health, Education, Labor, and Pensions Committee
  21. Apr 24, 2017IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  22. Apr 24, 2017IntroReferral10000

    Introduced in Senate

Public LawNov 2, 201749

(This measure has not been amended since it was passed by the Senate on September 6, 2017. The summary of that version is repeated here.)

National Clinical Care Commission Act

(Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, (4) methods for outreach and dissemination of education and awareness materials, and (5) opportunities for consolidation of overlapping federal programs.

The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

Passed House without amendmentOct 11, 201781

(This measure has not been amended since it was passed by the Senate on September 6, 2017. The summary of that version is repeated here.)

National Clinical Care Commission Act

(Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, (4) methods for outreach and dissemination of education and awareness materials, and (5) opportunities for consolidation of overlapping federal programs.

The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

Passed Senate amendedSep 6, 201735

National Clinical Care Commission Act

(Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, (4) methods for outreach and dissemination of education and awareness materials, and (5) opportunities for consolidation of overlapping federal programs.

The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

Reported to Senate without amendmentMay 1, 201780

(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)

National Clinical Care Commission Act

(Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, and (4) methods for outreach and dissemination of education and awareness materials.

The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

Introduced in SenateApr 24, 2017

National Clinical Care Commission Act

This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, and (4) methods for outreach and dissemination of education and awareness materials.

The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

National Clinical Care Commission Act — Informed